Discover
ABOS
Acumen Pharmaceuticals, Inc.
2.59
2 x 1.88
2 x 3.25
bid
ask
-
0.08
3.00%
2 @ 06:00 AM
2.58 -0.01 (0.39%)
| Ytd | 22.75% | |
| 1y | 133.33% |
2.50
day range
2.70
1.10
52 week range
3.60
| Open | 2.65 | Prev Close | 2.67 | Low | 2.50 | High | 2.70 | Mkt Cap | 187.07M |
| Vol | 299.10K | Avg Vol | 463.12K | EPS | -1.85 | P/E | N/A | Forward P/E | -1.17 |
| Beta | 0.04 | Short Ratio | 6.61 | Inst. Own | 78.46% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-11 | 50-d Avg | 2.43 | 200-d Avg | 2.27 | 1yr Est | 10.80 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2024-11-12 | 2024-09 | -0.36 | -0.5 | -0.14 | -38.89% |
| 2024-08-13 | 2024-06 | -0.28 | N/A | N/A | N/A |
| 2024-08-13 | 2024-06 | -0.28 | -0.34 | -0.06 | -21.43% |
| 2024-05-14 | 2024-03 | -0.23 | -0.25 | -0.02 | -8.70% |
| 2024-05-14 | 2024-03 | -0.23 | N/A | N/A | N/A |
| 2024-03-26 | 2023-12 | -0.29 | N/A | N/A | N/A |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2024-11-13 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2024-10-03 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2024-08-15 | UBS | Upgrade | Buy | Buy |
| 2024-08-14 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2024-07-25 | Citigroup | Upgrade | Buy | |
| 2024-05-15 | HC Wainwright & Co. | Upgrade | Buy | Buy |
Profile
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate sabirnetug (ACU193), a recombinant humanized immunoglobulin gamma 2 that completed Phase I clinical trial to target soluble amyloid-beta oligomers. The company has a license agreement with Lonza Sales AG to manufacture and commercialize sabirnetug; and a collaboration and license agreement with Halozyme, Inc. for the development of a subcutaneous formulation of sabirnetug. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2024-01-17 | BARTON RUSSELL | Chief Operating Officer | 96.87K | Sale |
| 2023-08-16 | IVES JEFFREY L | Director | 0.00 | Sale |
| 2024-01-18 | MEISNER DEREK M | Officer | 108.87K | Sale |
| 2024-01-18 | O'CONNELL DANIEL JOSEPH | Chief Executive Officer | 502.49K | Sale |
| 2023-07-20 | RA CAPITAL MANAGEMENT, L.P. | Director and Beneficial Owner of more than 10% of a Class of Security | 0.00 | Purchase |
| 2024-01-17 | SIEMERS ERIC M.D. | Officer | 117.58K | Sale |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-09-29 | RA Capital Management, L.P. | 14.93M | 26.73M | 24.85% |
| 2024-09-29 | Franklin Resources, Inc. | 3.55M | 6.35M | 5.91% |
| 2024-09-29 | Sands Capital Ventures, LLC | 3.42M | 6.12M | 5.69% |
| 2024-09-29 | Blackrock Inc. | 2.33M | 4.17M | 3.88% |
| 2024-09-29 | Rock Springs Capital Management, LP | 2.30M | 4.12M | 3.83% |
| 2024-09-29 | FMR, LLC | 2.03M | 3.63M | 3.38% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-07-30 | Franklin Strategic Series-Franklin Small Cap Growth Fund | 1.20M | 2.15M | 2.00% |
| 2024-09-29 | Vanguard Total Stock Market Index Fund | 1.15M | 2.05M | 1.91% |
| 2024-10-30 | Fidelity Select Portfolios - Health Care | 1.14M | 2.04M | 1.90% |
| 2024-10-30 | iShares Russell 2000 ETF | 1.01M | 1.81M | 1.68% |
| 2024-07-30 | Franklin Strategic Series-Franklin Biotechnology Discove | 826.40K | 1.48M | 1.38% |
| 2024-10-30 | Fidelity Advisor Health Care Fund | 700.00K | 1.25M | 1.17% |